Antibody‐Drug Conjugates for the Treatment of Cancer
暂无分享,去创建一个
[1] Scott T Phillips,et al. A self-immolative spacer that enables tunable controlled release of phenols under neutral conditions. , 2012, The Journal of organic chemistry.
[2] E. Giné,et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Hartley. The development of pyrrolobenzodiazepines as antitumour agents , 2011, Expert opinion on investigational drugs.
[4] K. Gelmon,et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. , 1999, Journal of Clinical Oncology.
[5] P. Frost,et al. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. , 2003, Current opinion in pharmacology.
[6] Damon L. Meyer,et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.
[7] B. Gunter,et al. The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates , 2012, Molecular Cancer Therapeutics.
[8] X. Wu,et al. Tumor specific novel taxoid-monoclonal antibody conjugates. , 2002, Current medicinal chemistry.
[9] Andrew T. Russell,et al. Self-immolative linkers in polymeric delivery systems , 2011 .
[10] P. Trail,et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.
[11] R. Chari,et al. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. , 2012, Journal of medicinal chemistry.
[12] N. Damle,et al. Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma , 2006, Clinical Cancer Research.
[13] X. H. Chen,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] P. Trail,et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.
[15] John M Lambert,et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.
[16] R. Chari,et al. Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.
[17] M. Brechbiel,et al. Targeting of Radio-Isotopes for Cancer Therapy , 2004, Cancer biology & therapy.
[18] Yelena Kovtun,et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. , 2006, Journal of medicinal chemistry.
[19] Kerry A Chester,et al. Antibody–drug conjugates – a perfect synergy , 2012, Expert opinion on biological therapy.
[20] Laurent Ducry,et al. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. , 2010, Bioconjugate chemistry.
[21] A. Mountain,et al. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. , 2005, Bioconjugate chemistry.
[22] Hongsheng Xie,et al. Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.
[23] J. Hartley,et al. DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057 , 2012, Investigational New Drugs.
[24] G. Dubowchik,et al. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. , 1998, Bioorganic & medicinal chemistry letters.
[25] S. Shah,et al. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. , 1995, Cancer research.
[26] M. Siegel,et al. Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin .gamma.1I , 1987 .
[27] H. W. Scheeren,et al. "Cascade-release dendrimers" liberate all end groups upon a single triggering event in the dendritic core. , 2003, Angewandte Chemie.
[28] A. Wahl,et al. Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. , 2002, The Journal of organic chemistry.
[29] D. Neri,et al. Antibody-drug conjugates: basic concepts, examples and future perspectives. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[30] P. Trail,et al. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates. , 1999, Bioconjugate chemistry.
[31] Irwin Hollander,et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.
[32] I. Hollander,et al. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. , 2008, Bioconjugate chemistry.
[33] D. Kroll,et al. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. , 2009, Bioconjugate chemistry.
[34] D. Goldenberg,et al. Designing immunoconjugates for cancer therapy , 2012, Expert opinion on biological therapy.
[35] Damon L. Meyer,et al. Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. , 2007, Bioorganic & medicinal chemistry letters.
[36] P. Trail,et al. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. , 2002, Journal of medicinal chemistry.
[37] I. Ojima. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads. , 2008, Accounts of chemical research.
[38] Naresh Chennamsetty,et al. Design and application of antibody cysteine variants. , 2010, Bioconjugate chemistry.
[39] R. Lutz,et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.
[40] Paul Polakis,et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.
[41] J. Knipe,et al. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. , 1998, Bioorganic & medicinal chemistry letters.
[42] I. Bernstein,et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.
[43] John M Lambert,et al. Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry , 2005, Protein science : a publication of the Protein Society.
[44] M. Cronauer,et al. Re: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2013 .
[45] P. Polakis. Arming antibodies for cancer therapy. , 2005, Current opinion in pharmacology.
[46] V. Ramakrishnan,et al. Investigational antibody-drug conjugates for hematological malignancies , 2011, Expert opinion on investigational drugs.
[47] A. Younes,et al. Brentuximab Vedotin (SGN-35) , 2011, Clinical Cancer Research.
[48] E. Gillies,et al. Design, synthesis, and cyclization of 4-aminobutyric acid derivatives: potential candidates as self-immolative spacers. , 2011, Organic & biomolecular chemistry.
[49] I. Bernstein,et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. , 2002, Bioconjugate chemistry.
[50] Rajeeva Singh,et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. , 2011, Journal of medicinal chemistry.
[51] P. Schultz,et al. Selective formation of covalent protein heterodimers with an unnatural amino acid. , 2011, Chemistry & biology.
[52] Gerhard Moldenhauer,et al. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. , 2012, Journal of the National Cancer Institute.
[53] Bonnie F. Sloane,et al. Unraveling the role of proteases in cancer. , 2000, Clinica chimica acta; international journal of clinical chemistry.
[54] J. Walton,et al. Ribosomal biosynthesis of the cyclic peptide toxins of Amanita mushrooms. , 2010, Biopolymers.
[55] S. Hitchcock,et al. Structural modifications that alter the P-glycoprotein efflux properties of compounds. , 2012, Journal of medicinal chemistry.
[56] C. J. O’Donnell,et al. Investigational antibody drug conjugates for solid tumors , 2011, Expert opinion on investigational drugs.
[57] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.